BLI secures $1.8 million to advance 3D bioprinting
As a result, Biological Lattice Industries is introducing its BioLoom multi-tool 3D bioprinter and Loominus Studio software
Biological Lattice Industries (BLI), an innovator in biofabrication and life sciences R&D, has secured a $1.8 million pre-seed investment led by Greek venture capital firm Uni.Fund. With this funding, BLI is introducing its all-in-one biofabrication solution: BioLoom, a multi-tool 3D bioprinter, and Loominus Studio, a unified software platform designed to revolutionize biofabrication workflows.
“We are thrilled to partner with Uni.Fund to bring our vision of democratizing biofabrication to life,” said Filippos Tourlomousis, Founder and CEO of Biological Lattice Industries. “This funding will allow us to accelerate the development of our unified platform, enabling researchers to work with greater precision, reproducibility, and efficiency.”
Current biofabrication workflows require coordinating multiple, non-integrated protocols and instruments. Loominus Studio integrates every aspect of the workflow, from design to fabrication – allowing researchers to automate complex processes, improve reproducibility, and reduce optimization efforts.
“Loominus Studio represents a new standard in biofabrication, allowing labs to focus on innovation rather than the technical challenges of integration,” said Tourlomousis. “Our goal is to make biofabrication as simple and intuitive as possible, empowering researchers to break through technical barriers.”
BioLoom is a versatile multi-tool extrusion-based 3D bioprinter capable of fabricating high-resolution, multi-material scaffolds and devices. Its Active Environmental Control feature ensures reproducibility and supports Good Manufacturing Practice (GMP) compliance, making it ideal for labs aiming to accelerate commercialization in life sciences.
“BioLoom provides an unparalleled level of versatility and precision,” said Tourlomousis. “It is designed to meet the needs of both academic and commercial labs, pushing the boundaries of biofabrication beyond traditional 3D bioprinting capabilities.”
“BLI is a game-changer in the biotech space, with a bold vision to disrupt how biofabrication is performed globally,” said Katerina Pramatari, Founding Partner at Uni.Fund. “Their integrated approach to life sciences R&D, combining sophisticated hardware and software powered by AI, is exactly the kind of innovation that Uni.Fund aims to support.”
BLI aims to establish Loominus as the industry standard for biofabrication labs – offering tools that simplify complex workflows. The investment will accelerate the availability of BioLoom and Loominus Studio, which are already deployed to leading academic labs through the company’s early adopter program.
